Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
NMRA
NMRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NMRA News
NMRA-511 Shows Promising Results in Alzheimer's Agitation
Feb 17 2026
Benzinga
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
Jan 07 2026
Benzinga
Neumora Reports NMRA-511 Alzheimer’s Study Results, Significantly Improves Patient Behavior
Jan 05 2026
Benzinga
Neumora (NMRA) Reports Positive Phase 1b Results for NMRA-511 in Alzheimer's Agitation
Jan 05 2026
NASDAQ.COM
ZIM Integrated Shipping Shares Surge 7.6% on Acquisition Proposals
Dec 23 2025
Benzinga
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
Dec 23 2025
NASDAQ.COM
Analyst Recognizes Potential in Neumora's Growing Obesity and Metabolic Portfolio
Dec 01 2025
Benzinga
Neumora Receives Upgrade from RBC Capital Markets Due to Obesity and Parkinson's Drug Potential
Dec 01 2025
SeekingAlpha
Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday
Dec 01 2025
Benzinga
RBC Capital Boosts Neumora Therapeutics Rating to Outperform and Increases Price Target to $7
Dec 01 2025
Benzinga
Stifel Keeps Hold Rating on Neumora Therapeutics and Increases Price Target to $3
Nov 17 2025
Benzinga
TECX, GKOS, GH, ALGN, NMRA Experience After-Hours Surge Following Clinical Data and Earnings Reports
Oct 30 2025
NASDAQ.COM
Needham Keeps Buy Rating on Neumora Therapeutics and Increases Price Target to $8
Oct 28 2025
Benzinga
Neumora to Launch Phase 1 Trial for Oral Obesity Medication
Oct 27 2025
SeekingAlpha
Neumora Therapeutics Reveals Superior Weight Loss Results with NMRA-215 in Preclinical Model of Diet-Induced Obesity
Oct 27 2025
Newsfilter
Show More News
